Ardelyx, Inc. (ARDX)

Market Cap	1.20B
Revenue (ttm)	333.62M
Net Income (ttm)	-39.14M
Shares Out	236.85M
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,741,113
Open	5.73
Previous Close	5.72
Day's Range	5.05 - 5.73
52-Week Range	4.32 - 9.83
Beta	0.85
Analysts	Buy
Price Target	9.93 (+96.25%)
Earnings Date	Feb 20, 2025

About ARDX

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of el...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2014
• Employees: 267
• Stock Exchange: NASDAQ
• Ticker Symbol: ARDX
• Website: https://www.ardelyx.com

Financial Performance

In 2024, Ardelyx's revenue was $333.62 million, an increase of 168.06% compared to the previous year's $124.46 million. Losses were -$39.14 million, -40.76% less than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for ARDX stock is "Buy." The 12-month stock price forecast is $9.93, which is an increase of 96.25% from the latest price.

Price Target

$9.93

(96.25% upside)

Analyst Consensus: Buy